secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001564590-22-008039
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon reports FY2021 net loss $78.9M; XEN1101 Phase 3 expected H2 2022
----------------------------------------------------------------------

- Net loss $78.9M vs $28.8M in 2020; revenue $18.4M vs $32.2M.
- Cash $551.8M (Dec 31, 2021) vs $177.0M; expects funding into at least 2024.
- XEN1101 Phase 2b met primary endpoint; end-of-Phase 2 FDA meeting Q2 2022; Phase 3 start H2 2022.
- XEN496 Phase 3 EPIK trial for KCNQ2-DEE enrolling; completion expected H1 2023.
- Partner Neurocrine Phase 2 for NBI-921352 ongoing; Pacira Phase 1b for PCRX301 data expected Q2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022008039/0001564590-22-008039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022008039/xene-8k_20220301.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-008039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer